Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B

Hepatology Research

Volumn 44, Issue 2, 2014, Pages 187-193

  Li, Xuefen ^a   Wang, Yiyin ^b   Han, Dongsheng ^b   Zhang, Wen ^b   Zhang, Zike ^b   Ye, Xianfei ^b   Tian, Li ^a   Dong, Yuejiao ^a   Zhu, Qiaoyun ^a   Chen, Yu ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Chronic hepatitis B; Hepatitis B surface antigen; Telbivudine; Treatment response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; TELBIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROCONVERSION; TREATMENT RESPONSE; VIRUS LOAD; YOUNG ADULT;

EID: 84893810501     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12105     Document Type: Article

References (23)

1. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26: 153-161.
2. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
3. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
4. Kohmoto M, Enomoto M, Tamori A etal. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 2005; 75: 235-239.
5. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
6. Wursthorn K, Lutgehetmann M, Dandri M etal. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684.
7. Chan HL, Wong VW, Tse AM etal. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468.
8. Ozaras R, Tabak F, Tahan V etal. Correlation of quantitative assay of HBsAg and HBV-DNA levels during chronic HBV treatment. Dig Dis Sci 2008; 53: 2995-2998.
9. Sonneveld MJ, Zoutendijk R, Janssen HL. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat 2011; 18: 449-457.
10. Janssen HL, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res 1994; 23: 251-257.
11. Moucari R, Mackiewicz V, Lada O etal. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157.
12. Song JC, Min BY, Kim JW etal. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Korean J Hepatol 2011; 17: 268-273.
13. Cai W, Xie Q, An B etal. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48: 22-26.
14. Jung YK, Kim JH, Lee YS etal. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol 2010; 44: 653-657.
15. Nash K. Telbivudine in the treatment of chronic hepatitis B. Adv Ther 2009; 26: 155-169.
16. Liaw YF, Gane E, Leung N etal. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
17. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl) 2007; 120: 2159-2173.
18. Chen Y, Li X, Ye B etal. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res 2011; 91: 23-31.
19. Lai CL, Gane E, Liaw YF etal. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588.
20. Lai CL, Leung N, Teo EK etal. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-536.
21. Lee JM, Ahn SH, Kim HS etal. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53: 1486-1493.
22. Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009; 46: 117-123.
23. Lee JM, Ahn SH. Quantification of HBsAg: basic virology for clinical practice. World J Gastroenterol 2011; 17: 283-289.